A poster titled, “Precision Medicine Enabled Benefits Management for Diabetes and Weight Loss Management” was presented at the ISPOR 2025 conference by authors Vinny Marino, Craig Davis, Neil Shah, MD, and Saurabh Gombar, MD, PhD.
Short Summary:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for type 2 diabetes and weight loss management but come with significant cost challenges for health plans. Alternative lower cost therapies have shown efficacy in diverse patient populations but the lack of precision clinical guidelines makes weight management benefit design difficult.
Atropos Health generated real-world evidence (RWE) to compare weight loss therapies against in-class alternatives across over 1,620 patient subpopulations. The analysis identified scenarios where GLPs were cost-effective and others where lower-cost therapies provided similar clinical benefit. This subpopulation-driven model allows payers to optimize GLP access where clinical and economic value align while promoting alternatives when appropriate.
To learn how Atropos Health can accelerate and supplement your research with real-world evidence (RWE), email us: sales@atroposhealth.com